The firms will use nFerence's Agentic AI platform to analyze real-world treatment patterns in 700 patients' charts and inform personalized care.

Researchers have found that targeting an enzyme called PGM3 can help stop the growth of glioblastoma, the most dangerous type ...

A major new study has revealed that the genes we inherit at birth play a much larger role in cancer than previously ...

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, April 14, 2025 /PRNewswire/ -- Equity Insider News Commentary - Routine medical ...

Forecasts show cancer's global footprint expanding sharply, with annual case counts expected to rise 20% by 2030 and swell by 75% by mid-century, according to Statista. Meanwhile, Precedence Research ...

Health policy is crucial for advancing clinical research and ensuring accessibility and funding for novel therapies.

BeiGene has decided to end the clinical development program for ociperlimab (BGB-A1217) as a treatment for lung cancer.

Nearly a year after winning an accelerated approval for its DLL3-targeting small cell lung cancer (SCLC) therapy Imdelltra, ...

Treatment resistance and relapse in the most common type of lung cancer can be traced to a protein called agrin, according to ...

Amgen today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or ...

BeiGene (NasdaqGS:ONC) has climbed 32% over the past quarter, against a backdrop of significant industry challenges and broad market declines. The company's positive momentum can be attributed to the ...

Beigene Ltd. said it is shutting down development of its anti-TIGIT antibody, ociperlimab (BGB-A1217), after the humanized IgG1-variant monoclonal antibody failed a phase III trial in lung cancer. The ...